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Does the multidimensional grading system 
(BODE) correspond to differences in health 
status of patients with COPD?
Study objectives: To verify whether and to what extent the body mass index, airﬂ  ow 
obstruction, dyspnea, and exercise capacity (BODE) index correlates with a disease-speciﬁ  c 
index of health status in patients with COPD. 
Design: Cross-sectional study. 
Setting: University-afﬁ  liated hospital.
Patients: One hundred patients with stable COPD recruited from the outpatient clinic of a 
single institution.
Measurements: The BODE index was calculated for each patient using variables obtained 
within 2 weeks of enrollment. At enrollment, all patients completed the St George’s Respiratory 
Questionnaire (SGRQ). The Kruskal-Wallis test was used to compare health status scores 
with clinical and functional categories of COPD. The Spearman correlation coefﬁ  cient (r) 
was calculated to assess the association between health status scores and clinical or functional 
variables.
Results: Categorizing the BODE scores into 4 quartiles, we found that higher BODE quartiles 
were associated with higher (worse) SGRQ scores. The differences among the BODE quartiles 
in health status indexes were signiﬁ  cant for total SGRQ as well as all 3 of the SGRQ sub-
scales. In all sections of the SGRQ, scores were moderately to strongly associated with the 
BODE quartiles (r = 0.27–0.46). In contrast, the association between the SGRQ total, impacts, 
activity and Global Initiative for Chronic Obstructive Lung Disease (GOLD) stages were 
weaker (r = 0.27–0.28). There was no signiﬁ  cant association between SGRQ symptoms and 
GOLD stages.
Conclusions: The BODE scoring system corresponds to important differences in health status 
of patients with COPD. This grading system is better correlated to the health status indexes of 
the SGRQ than the GOLD staging criteria.
Keywords: body mass index, airﬂ  ow obstruction, dyspnea, exercise capacity, quality of life, 
questionnaire
Introduction
Chronic obstructive pulmonary disease has been described as a slowly progressive 
disorder characterized by airﬂ  ow obstruction that is not fully reversible (GOLD 
Expert Panel 2003). The spirometry-derived parameter, the FEV1, is a simple and 
valid measurement of the degree of airﬂ  ow obstruction and is often used as a prag-
matic surrogate for disease severity in COPD. Nonetheless, COPD is a complex 
multidimensional disease, and using the degree of airﬂ  ow obstruction alone to predict 
outcomes has limitations. FEV1 is known to correlate poorly with patients’ symp-
toms (Mahler et al 1984), quality of life (Jones et al 1992), exacerbation frequency 
(Alsaeedi et al 2002), and exercise intolerance (O’Donnell et al 1998). Hence newer 
approaches to disease assessment are required and may even supersede the current International Journal of COPD 2006:1(1) 92
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FEV1-based system of classiﬁ  cation of disease severity 
(Calverley 2004). Recently, the body mass index, airﬂ  ow 
obstruction, dyspnea, and exercise capacity (BODE) index, 
a multidimensional grading system, was shown to be better 
than the FEV1 at predicting the risk of death among patients 
with COPD (Celli et al 2004). This multistage scoring 
system that incorporates an assessment of symptoms, body 
habitus, and exercise capacity, together with the spirometric 
measure of airﬂ  ow (FEV1), can provide useful prognostic 
information in COPD. 
It is increasingly recognized that survival and physiologi-
cal measures by themselves do not represent the full experi-
ences of patients with COPD. There has been a substantial 
increase in the use of developed tools that measure health 
status as clinicians and researchers realize that improving 
patients’ symptoms, functional status, and quality of life are 
important goals in the management of COPD (Curtis and 
Patrick 2003). Although the BODE index has been shown to 
be a predictor of the risk of death, it is not known whether this 
index is a useful indicator of patients’ health status as well. 
Previously, it has been shown that the FEV1-based staging 
system by the Global Initiative for Chronic Obstructive Lung 
Disease (GOLD) corresponds to important differences in 
health status (Antonelli-Incalzi et al 2003). We hypothesized 
that the BODE index would better correlate with health status 
in COPD than the FEV1 alone. The purpose of this study is to 
verify whether and to what extent the BODE index correlates 
with a disease-speciﬁ  c index of health status in patients with 
stable COPD. 
Methods
Study sample
Between October 2003 and April 2004, patients with a 
wide range of severity of COPD, regardless of whether 
they had previous COPD admissions or not, were recruited 
from a single institution and enrolled in the Health Service 
Development Program (HSDP) for COPD funded by the 
Ministry of Health, Singapore. This pilot service project 
provided several interventions: optimal medication, patient 
education, home care, and telephonic support, and is aimed 
at reducing hospitalization for COPD. The main outcome 
measure monitored in this project was the frequency of 
hospital admissions for COPD. Patients were recruited from 
the outpatient clinic. A diagnosis of COPD was established 
by a respiratory physician based on medical history, current 
symptoms, and available pulmonary function tests, following 
the GOLD guidelines (GOLD Expert Panel 2003). All 
patients had COPD related to smoking. At enrollment, all 
patients were clinically stable (respiratory symptoms and 
medication unchanged for at least 4 weeks) and receiving 
appropriate therapy. The exclusion criteria were an illness 
other than COPD that was likely to result in death within 
2 years; bronchial asthma, deﬁ  ned as an increase in the FEV1 
of more than 15% above the baseline value or of 200 mL after 
the administration of a bronchodilator; an inability to perform 
the lung function and 6-minute walk tests; a myocardial 
infarction within the preceding 4 months; unstable angina; 
or congestive heart failure (New York Heart Association 
class III or IV). Patients with signiﬁ  cant bronchiectasis 
and/or pulmonary tuberculosis were also excluded. The 
present study is a cross-sectional analysis of the patients’ 
baseline variables on entry in the HSDP project for COPD. 
The study protocol was approved by the institutional ethics 
committee.
Patient evaluation
At enrollment, all patients completed the Singapore–
English or Singapore–Chinese versions of the St George’s 
Respiratory Questionnaire (SGRQ). The SGRQ is a 
standardized, self-administered pulmonary-speciﬁ  c health 
status questionnaire containing 50 items and 76 weighted 
responses that is divided into 3 subscales: symptoms 
(8 items), activity (16 items), and impacts (26 items). 
SGRQ scores were calculated using score calculation 
algorithms and missing data imputation recommended 
by its developer. For each subscale and for the overall 
questionnaire, scores range from zero (no impairment) to 
100 (maximum impairment).
The BODE index was calculated for each patient 
using variables obtained within 2 weeks of enrolment. 
For calculation of the BODE index, we used the empirical 
model as previously described (Celli et al 2004) and as 
shown in Table 1: for each threshold value of FEV1, distance 
walked in 6 minutes, and score on the modiﬁ  ed Medical 
Research Council (MMRC) dyspnea scale (Mahler and 
Wells 1988), the patients received points ranging from 0 
(lowest value) to 3 (maximal value). For body mass index 
the values were 0 or 1. The points for each variable were 
added, so that the BODE index ranged from 0 to 10 points 
in each patient. The post-bronchodilator FEV1 as a percent 
of the predicted value (Chia et al 1993) was used and clas-
siﬁ  ed according to the 3 stages identiﬁ  ed by the American International Journal of COPD 2006:1(1) 93
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Thoracic Society (ATS 1995). The best of two 6-minute 
walk tests performed at least 30 minutes apart (ATS 2002) 
was used for scoring.
Statistical analysis
The Kruskal-Wallis test (with correlation for ties when neces-
sary) was used to compare health status scores with clinical 
and functional categories of COPD. Differences between 
stages were assessed using the Mann-Whitney U test. The 
Spearman correlation coefﬁ  cient (r) was calculated to assess 
the association between health status scores and clinical 
or functional variables. Analysis of data was performed 
using the Statistical Package for the Social Sciences (SPSS) 
version10. 
Results
One hundred patients were enrolled during the study 
period. The general characteristics of the patients are 
summarized in Table 2. All patients were either current 
smokers or ex-smokers. The mean + SD duration of 
smoking is 37.4 + 15.3 years. The minority (16 patients) 
were current smokers and only 1 patient lived alone. The 
population was geriatric and poorly educated with only 
7 patients having more than 8 years of formal education. 
The average nutritional status expressed by the body mass 
index was normal. Five patients had respiratory failure as 
deﬁ  ned by arterial partial pressure of oxygen (PaO2) less 
than 60 mmHg with or without arterial partial pressure 
of carbon dioxide (PaCO2) greater than 50 mmHg while 
breathing air at sea level. These 5 patients were receiv-
ing long-term oxygen therapy. Thirty-eight patients had 
signiﬁ  cant comorbid conditions. The 4 most common 
comorbid conditions were hypertension (30 patients), 
ischemic heart disease (18), prostatic hypertrophy (6), and 
visual impairment (4). Table 3 shows the classiﬁ  cation of 
patients according to airﬂ  ow obstruction and BODE index 
score. The vast majority of patients had moderate to very 
severe COPD (stages II to IV) according to the GOLD 
staging of severity. 
Categorizing the BODE scores into 4 quartiles (Celli 
et al 2004) as follows: quartile 1 is a score of 0–2; quartile 
2 is a score of 3–4; quartile 3 is a score of 5–6; and quartile 
4 is a score of 7–10, we found that higher BODE quartiles 
were generally associated with higher (worse) SGRQ scores 
(Table 4). This pattern is shown clearly by the SGRQ total 
scores (Figure 1). The differences among the BODE quartiles 
in health status indexes assessed by the Kruskal-Wallis test 
were signiﬁ  cant for total SGRQ as well as all 3 of the SGRQ 
subscales. Post-hoc analysis of the differences between 
BODE quartiles showed important differences in SGRQ total, 
Table 1 Variables and point values used for the computation 
of the BODE index
Variable  Points on BODE index
 0  1  2  3
FEV1 (% predicted)a  >65 50–64 36–49  <35
Six-minute walk distance (m)  >350  250–349  150–249  <149
MMRC dyspnea scaleb  0–1 2 3  4
Bodymass index (kg/m2) >21  <21   
Data adapted from Celli et al (2004). The cut-off values for the assignment of 
points are shown for each variable; the total possible values range from 0 to 10.
a The FEV1 categories were identiﬁ  ed by the American Thoracic Society (1995).
b  Scores on the modiﬁ  ed Medical Research Council (MMRC) dyspnea scale can 
range from 0 to 4, with a score of 4 indicating that the patient is too breathless to 
leave the house or becomes breathless when dressing or undressing.
Table 2 General characteristics of the patientsa
Male:Female 90:10
Age (years)  70.8 ± 7.9
Body mass index (kg/m2)  21.5 ± 3.9
FEV1
b (L)  1.13 ± 0.44
FEV1
b (% predicted)  48.8 ± 20.4
FVC (L)  1.99 ± 0.57
MMRC dyspnoea scalec   1.7 ± 1.1
Six-minute walk distance (m)  366.1 ± 132.2
BODE index score  3.6 ± 2.3
a Values are means ± SD except male:female ratio.
b Post-bronchodilator values are shown.
c   Scores on the modiﬁ  ed Medical Research Council (MMRC) dyspnea scale can 
range from 0 to 4, with a score of 4 indicating that the patient is too breathless 
to leave the house or becomes breathless when dressing or undressing.
Table 3 Classiﬁ  cation of patients according to airﬂ  ow 
obstruction and BODE index score 
Characteristic   Nr of patients (%)
Severity of COPDa 
Stage I (FEV1 > 80% predicted)  10 (10)
Stage II (50% < FEV1 < 80% predicted)  30 (30)
Stage III (30% < FEV1 < 50% predicted)  45 (45)
Stage IV (FEV1 < 30% predicted or FEV1 
   < 50% predicted, plus chronic respiratory failure)  15 (15)  
BODE index score 
0–2 34  (34) 
3–4 32  (32)
5–6 22  (22)
7–10 11  (11)
a   Stage I–IV of COPD were deﬁ  ned by the Global Initiative for Chronic 
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Table 4 Mean SGRQ scores by BODE quartiles and the 
Global Initiative for Chronic Obstructive Lung Disease (GOLD) 
stagesa
  St George’s Respiratory Questionnaire Score
Characteristic Symptoms Activity  Impacts  Total
BODE index    
0–2 (n=34)  28 ± 22   25 ± 18  17 ± 17  22 ± 15
3–4 (n=32)  40 ± 20  27 ± 17  22 ± 13  27 ± 13
5–6 (n=22)  36 ± 22  33 ± 23  23 ± 17  30 ± 17
7–10 (n=11)  50 ± 24  67 ± 17  46 ± 19  53 ± 17
p valueb   0.024  <0.001  0.001  <0.001         
GOLD classiﬁ  cation    
Stage I (n=10)  29 ± 20  26 ± 18  18 ± 19  24 ± 16
Stage II (n=30)  35 ± 23  27 ± 19  19 ± 15  25 ± 17
Stage III (n=45)  38 ± 23  30 ± 21  22 ± 15  27 ± 14
Stage IV (n=15)  39 ± 20  52 ± 26  37 ± 22  42 ± 22
p-valuec   0.533  0.007  0.019  0.030
a  Data are presented as mean ± SD.
b   For relation between SGRQ score and BODE index quartile (Kruskal-Wallis 
test).
c  For relation between SGRQ score and COPD stage (Kruskal-Wallis test).
activity, and impacts between nonconsecutive quartiles but 
only between consecutive quartiles 3 and 4. The only con-
secutive quartiles signiﬁ  cantly differing in SGRQ symptoms 
were quartiles 1 and 2.
The differences in health status indexes among the GOLD 
stages of severity as assessed by the Kruskal-Wallis test was 
signiﬁ  cant for all except the SGRQ symptoms (Table 4). The 
SGRQ total, activity, and impacts scores worsened from 
stage I to stage IV, but the only consecutive stages differing 
in these indexes were III and IV. 
In all sections of the SGRQ, scores were positively as-
sociated with the BODE index quartiles (r = 0.27–0.46). In 
contrast, the association between the SGRQ total, impacts, 
activity, and GOLD severity stages were weaker (r = 0.27–
0.28). There was no signiﬁ  cant association between SGRQ 
symptoms and GOLD stages (Table 5).
Discussion
The main ﬁ  nding of this study is that the BODE staging 
system (Celli et al 2004), which includes in addition to FEV1 
Table 5 Correlation between 2 COPD staging systems and St George’s Respiratory Questionnaire scoresa 
  St George’s Respiratory Questionnaire Score
COPD staging systems  Symptoms  Activity  Impacts  Total
BODE index quartiles  0.27 (0.008)  0.38 (<0.001)  0.34 (0.001)  0.46 (<0.001)
GOLD stages  0.13 (0.190)  0.28 (0.006)  0.28 (0.004)  0.27 (0.008)
a Values shown are Spearman’s correlation coefﬁ  cients with corresponding p-values in parentheses.
other physiologic and clinical variables, corresponds to 
important differences in health status of patients with COPD. 
Furthermore, the BODE scoring system is better correlated 
to health status as assessed by a disease-speciﬁ  c index for 
COPD than the GOLD staging criteria based largely on the 
FEV1.
COPD is a complex multidimensional disease, and 
classiﬁ  cation schemes that incorporate more parameters 
than the degree of airﬂ  ow obstruction are likely to predict 
outcomes more accurately (Rennard 2004). The multistage 
scoring system used in this study incorporates variables 
that can be easily evaluated in any ofﬁ  ce setting, and the 
BODE index has potential widespread applicability, just 
like the FEV1. Important to the acceptance for use of this 
new classiﬁ  cation system is the evidence to support that it 
provides more useful information than the FEV1 alone. The 
multidimensional staging system of the BODE index has 
already been shown to be a superior predictor of the risk 
of death in COPD patients compared with the FEV1-based 
staging system by the ATS (Celli et al 2004). Recently the 
Figure 1 Box plot showing the distribution of St George’s Respiratory 
Questionaire (SGRQ) scores by BODE quartiles. Error bars show SD; horizontal 
lines within boxes show the mean.
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BODE index was also reported to be a much better predictor 
of the severity in COPD acute exacerbations than the FEV1 
(Marin et al 2003). Additionally, the BODE index is also 
responsive to changes resulting from exacerbations and may 
capture the impact of exacerbations in patients with COPD 
(Cote and Celli 2004).
The relation between both the ATS and GOLD systems 
for staging COPD with health status has been examined 
previously (Ferrer et al 1997; Antonelli-Incalzi et al 2003). 
With both staging systems, the effect of COPD on health 
status assessed by the SGRQ increases as the disease 
severity worsens. In a previous study (Antonelli-Incalzi 
et al 2003), the GOLD staging of COPD corresponded to 
important differences in health status between stages II 
and III (previously labeled stages IIa and IIb, respectively), 
but not between other consecutive stages. The authors 
concluded that passing the boundary of a FEV1 of <50% 
of predicted is likely to herald a dramatic decline in health 
status. We observed a lower potential turning point in 
the evolution of health status in our study population, ie, 
between stages III and IV, with no signiﬁ  cant change in 
SGRQ total scores marking the progression of COPD from 
stage I to III. Differences in study populations may explain 
these ﬁ  ndings. In particular, fewer patients in the present 
study had signiﬁ  cant comorbid conditions compared with 
previous studies, in part due to the stringent exclusion cri-
teria. Consistent with the GOLD classiﬁ  cation, important 
differences in health status between the highest quartiles 
(quartiles 3 and 4) of the BODE classiﬁ  cation system were 
observed but not between lower grade consecutive quartiles. 
This suggests that health status may be relatively preserved 
in these patients till the disease is very advanced and every 
effort should thus be made to prevent disease progression 
even in severe COPD before a dramatic decline of health 
status occurs.
To our knowledge, this is the ﬁ  rst study that has shown 
the BODE staging system to be generally better correlated 
with health status than current COPD classiﬁ  cation based 
on the FEV1. Nonetheless, it is noteworthy that the multi-
dimensional staging system of the BODE index accounted 
for a minority of the explained variance in SGRQ total score 
and health status patterns of consecutive BODE quartiles 
overlap remarkably. This ﬁ  nding of a great interindividual 
variability in health status within a given BODE quartile 
clearly shows that the health status cannot be inferred from 
the BODE index and should be systematically assessed in 
the individual patient. Although the ﬁ  ndings of the present 
study are in support of the utility of the BODE index as 
an assessment tool for COPD patients compared with the 
sole measurement of airﬂ  ow obstruction, the BODE index 
cannot be recommended as a valuable alternative to a 
disease-speciﬁ  c instrument for evaluation of health status. 
Further research is needed to verify whether integrating the 
BODE index with selected measures of health status will 
allow deﬁ  nition of subgroups with distinctive prognosis. 
Few interventions can affect the decline of FEV1 in COPD 
patients but modalities such as medications and exercise 
training may impact on the other components of the BODE 
scoring system, namely exercise tolerance and dyspnea 
level. Prospectively assessing the BODE index in response 
to treatment or exacerbations will improve knowledge of the 
BODE classiﬁ  catory and prognostic implications, as well 
as of the feasibility of a mixed, ie, physiological-clinical 
and health-status indicator based COPD staging system. 
Prospective follow-up studies will also be required for 
comparison of treatment responses of BODE and SGRQ 
scores. 
Several limitations of this study require discussion. First, 
survival bias might have attenuated the differences between 
the most severe cases. Only a longitudinal study can test 
this hypothesis. Second, the lack of statistically signiﬁ  cant 
differences between consecutive stages other than stages III 
and IV of the GOLD classiﬁ  cation and quartiles 3 and 4 
of the BODE staging system does not mean that clinically 
signiﬁ  cant differences were absent. For instance, BODE 
quartiles 1 and 2 differed in SGRQ total and impacts 
score by 5 points, ie, of a magnitude over the clinically 
relevant minimal difference of four (Jones et al 1992). 
Such differences may qualify as statistically signiﬁ  cant in 
a larger population. Third, none of the patients in this study 
who were recruited from a hospital outpatient clinic were 
of GOLD stage 0 and hence not all stages of the current 
GOLD classiﬁ  cation that identiﬁ  es 5 stages of COPD are 
evaluated here. However, we do not consider that absence 
of stage 0 is likely to affect the conclusions of this study 
since stage 0, the presence of symptoms without airﬂ  ow 
limitation, was conceived of as an opportunity for early 
identiﬁ  cation of the disease rather than a precursor of illness 
in all cases in the current form of the GOLD classiﬁ  cation 
(Calverley 2004).  
In summary, the BODE scoring system corresponds to 
important differences in health status of patients with COPD. 
This grading system is better correlated to health status as 
assessed by a disease-speciﬁ  c index for COPD than the 
GOLD staging criteria.International Journal of COPD 2006:1(1) 96
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